期刊
AUTOIMMUNITY REVIEWS
卷 12, 期 6, 页码 670-673出版社
ELSEVIER
DOI: 10.1016/j.autrev.2012.10.013
关键词
Alzheimer's disease; Down's syndrome; Clearing amyloid-beta peptide; Inhibiting synthesis of amyloid-beta peptide
类别
资金
- CSL Behring, Fox Chase, PA, USA
Successful therapy of dementia, like any disease, depends upon understanding its pathogenesis. This review contrasts the dominant pathways to dementia which differ in Alzheimer's disease (AD) and in Down's syndrome (DS). Impaired clearance of neurotoxic amyloid beta peptides (Abeta) leads to dementia in AD. In DS over-production of Abeta plays the dominant role in the development of dementia. It follows, therefore, that the therapy of AD and DS should reflect a different balance between the dominant agent that inhibits the synthesis of Abeta in the brain in AD and increase the clearance of Abeta from the cerebrospinal DS. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据